Generation of CAR-T Cells for Cancer Immunotherapy
- PMID: 30465215
- DOI: 10.1007/978-1-4939-8885-3_24
Generation of CAR-T Cells for Cancer Immunotherapy
Abstract
T cells engineered with chimeric antigen receptors (CARs) are emerging as powerful cancer immunotherapies. Remarkable efficacies have been demonstrated in treating B-cell malignancies with CAR-T cells, leading to the FDA's first approval of gene therapy. Currently, numerous clinical trials for hematological malignancies and solid tumors are underway worldwide. Production of CAR-T cells with proper qualities is essential for CAR-T success in vivo. Here we detail optimized protocols for the generation of CAR-T cells for preclinical studies using lentiviral gene transfer, expansion of CAR-T cells in culture, detection of CAR expression, and evaluation of CAR-T cellular cytotoxicity in vitro.
Keywords: Adoptive cell therapy; Cancer immunotherapy; Chimeric antigen receptor; Lentiviral gene transfer; T cells.
Similar articles
-
In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.Methods Mol Biol. 2019;2048:85-91. doi: 10.1007/978-1-4939-9728-2_10. Methods Mol Biol. 2019. PMID: 31396933
-
Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors.Methods Mol Biol. 2019;2048:27-39. doi: 10.1007/978-1-4939-9728-2_3. Methods Mol Biol. 2019. PMID: 31396926
-
Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.J Gene Med. 2018 Jul;20(7-8):e3027. doi: 10.1002/jgm.3027. Epub 2018 Jul 6. J Gene Med. 2018. PMID: 29851200
-
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29861325 Review.
-
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Front Immunol. 2018. PMID: 29515572 Free PMC article. Review.
Cited by
-
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.Recent Pat Anticancer Drug Discov. 2024;19(5):557-572. doi: 10.2174/0115748928277331231218115402. Recent Pat Anticancer Drug Discov. 2024. PMID: 38213150 Review.
-
DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.Cancers (Basel). 2019 Dec 23;12(1):54. doi: 10.3390/cancers12010054. Cancers (Basel). 2019. PMID: 31878090 Free PMC article.
-
Hypoxia Selectively Impairs CAR-T Cells In Vitro.Cancers (Basel). 2019 Apr 30;11(5):602. doi: 10.3390/cancers11050602. Cancers (Basel). 2019. PMID: 31052261 Free PMC article.
-
Immune gene therapy of cancer.Turk J Med Sci. 2020 Nov 3;50(SI-2):1679-1690. doi: 10.3906/sag-2005-327. Turk J Med Sci. 2020. PMID: 32512674 Free PMC article. Review.
-
Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy.Antibodies (Basel). 2021 Apr 26;10(2):17. doi: 10.3390/antib10020017. Antibodies (Basel). 2021. PMID: 33925949 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
